



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 5, 2009

To: Primary Clinical Research Associates

From: Linda S. Long
Research Protocol Specialist III

Re: **N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma**

The Evaluation/Treatment Forms for both Arm A and Arm B have been revised as follows:

Form Title	Brief Description of Edit
Evaluation/Treatment Form (Arm A)	<ul style="list-style-type: none">• Added "Ocular/Visual" and "Pain" to page 1• Added "(Days 1-28)" on page 2 of 2 after Dose (Level) modification (Erlotinib)• Added "Ocular/Visual" and "Pain" to page 2
Evaluation/Treatment Form (Arm B)	<ul style="list-style-type: none">• Added "Ocular/Visual" and "Pain" to page 1• Added "(Days 1-28)" on page 3 after Dose (Level) modification (Erlotinib)• Added "Ocular/Visual" and "Pain" to page 3

If you have any questions, please feel free to contact me.

Enclosure